Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

931.95 +28.47 (+3.15%)
Streaming Delayed Price Updated: 11:50 AM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
5 Stocks At the Forefront of the Latest S&P 500 Rally
Here are five stocks in the S&P 500 that led the market higher amid the uncertainty. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Regeneron Touts Mid-Stage Win For Higher Dose Of Eylea In Age-related Macular Degeneration
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) revealed new Phase 2 proof-of-concept trial data on Eylea (aflibercept) injection in patients with wet age-related... 
Via Benzinga
The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23) AbbVie Inc. (NYSE: ABBV) (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Understanding Regeneron Pharmaceuticals's Unusual Options Activity
On Friday, shares of Regeneron Pharmaceuticals (NASDAQ:REGN 
Via Benzinga
Return on Capital Employed Insights for Regeneron Pharmaceuticals
After pulling data from Benzinga Pro it seems like during Q2, Regeneron Pharmaceuticals (NASDAQ:REGN) earned $3.35 billion, a 200.82% increase from the preceding quarter.... 
Via Benzinga
Tesla And The Quest For Alpha
Tesla exemplifies both the successes and failures of our security selection method. How it works and where we go from here. 
Via Talk Markets
Market Briefing For Monday, Aug. 23
We might be near a moment of truth for the Senior Indexes, either in just a few days or postponed until after Labor Day. 
Via Talk Markets
Regeneron Pharmaceutical Stock Earns 84 Relative Strength Rating
A Relative Strength Rating upgrade for Regeneron Pharmaceutical shows improving technical performance. 
Via Investor's Business Daily
Exposures COVID-19
UK Approves Regeneron - Roche's COVID-19 Antibody Cocktail
The U.K. drug regulator has approved an antibody cocktail developed by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holding AG (OTC: RHHBY) to prevent... 
Via Benzinga
Exposures COVID-19
Stocks That Hit 52-Week Highs On Friday
Before 10 a.m. ET on Friday, 52 companies hit new 52-week highs. Highlights: Microsoft (NASDAQ:MSFT) was the biggest company by market cap to set a new 52-week high... 
Via Benzinga
PreMarket Prep Stock Of The Day: Regeneron
Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news... 
Via Benzinga
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Stocks That Hit 52-Week Highs On Wednesday
Before 10 a.m. ET on Wednesday, 77 companies hit new 52-week highs. Areas of Significance: Pfizer (NYSE:PFE) was the largest firm on a market cap basis to set a new... 
Via Benzinga
5 Stocks Insiders Are Selling
When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to... 
Via Benzinga
JD.com And Tesla Lead The Nasdaq Lower Tuesday
U.S. indices were trading lower Tuesday amid macro uncertainty due to COVID-19 concerns. Investors also weighed today's Home Depot (NYSE: HD) earnings and a drop in... 
Via Benzinga
Exposures COVID-19
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET on Tuesday, 55 companies set new 52-week highs. Points of Interest: Apple (NASDAQ:AAPL) was the largest company by market cap to set a new 52-week... 
Via Benzinga
Novartis Shares Two Year Beovu Data From Diabetic Macular Edema Studies
Novartis AG (NYSE: NVS) has reported data from two Phase 3 trials assessing Beovu (brolucizumab) 6 mg versus Regeneron Pharmaceuticals Inc's (NASDAQ: REGN... 
Via Benzinga
3 Growth Stocks Cathie Wood Is Selling That Are Still Worth Buying
Wood might regret trimming her positions in these great growth stocks. 
Via The Motley Fool
Large Cap Biopharma Stocks provide Growth and Value
The S&P 500 Healthcare Index was up 0.53% and biotech still lags in healthcare yet Large Cap Biopharma is doing well YTD. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Regeneron's Antibody Cocktail Authorized for Preventing COVID: Why It's Not a Big Deal for the Stock
The biotech's EUA expansion for REGEN-COV will probably provide only an incremental sales boost. 
Via The Motley Fool
Exposures COVID-19
eBay And AMD Lead The QQQ Friday
U.S. indices traded flat for much of Friday’s session as concerns over the COVID-19 Delta variant continues to cause market uncertainty. The Invesco QQQ Trust Series 1... 
Via Benzinga
Exposures COVID-19
Vaccine Stocks Fly On Booster Shot OK, But Their Run Could Be Short-Lived
Vaccine stocks popped Friday after the FDA authorized a third dose of their Covid shots from some immunocompromised people. 
Via Investor's Business Daily
Exposures Product Safety
What Rinvoq's Positive News Means for AbbVie
If the drug can overcome JAK inhibitor-class concerns, it could capture share in the growing atopic dermatitis market. 
Via The Motley Fool
Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases
Ocular Therapeutix Inc (NASDAQ: OCUL) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have terminated the option and license agreement collaboration. The... 
Via Benzinga
Regeneron Pharmaceuticals Inc (REGN) Q2 2021 Earnings Call Transcript
REGN earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Exicure Shares Interim Cavrotolimod Data From Early-Stage Trial In Solid Tumor Patients
Exicure Inc (NASDAQ: XCUR) has reported interim results from Phase 1b/2 trial evaluating cavrotolimod (AST-008) in patients with advanced or metastatic solid... 
Via Benzinga
Delta, Lambda Covid Variants Still Weighing On Market Despite Positive Earnings Reports
The market is still in a waiting mode, with a lot hinging on tomorrow’s jobs report. Predictions of a volatile, choppy week in the equity markets did not disappoint on... 
Via Benzinga
Sanofi - Regeneron's Libtayo/Chemo Treatment Improves Overall Survival First-Line Lung Cancer
The Phase 3 trial of Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo in combination with platinum-doublet chemotherapy... 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.